The AHA and other plaintiffs late Friday asked a federal district judge to set a firm June deadline for the Department of Health and Human Services to propose remedies to the nearly 30 percent cuts to Medicare payments affecting certain hospitals that participate in the 340B Drug Pricing Program. The judge last week had set an Aug. 5 deadline for the remedies.
 
In the filing, the plaintiffs said 鈥渋t is important that the Court require HHS to propose its remedy by the end of June 2019 or shortly thereafter, since unless there is a Court order on the remedy in this case this summer, Defendants may issue a 2020 OPPS [outpatient prospective payment system] rule reducing reimbursements for 340B drugs by nearly 30 percent in violation of law, just as they did in 2018 and 2019.鈥 While the final OPPS rule generally is issued by the Centers for Medicare & Medicaid Services in November, the agency typically issues its proposal in late July. 
 
A federal district court judge last week said HHS would get "first crack at crafting appropriate remedial measures" to the cuts, and also held that, like the 2018 cuts, the 2019 cuts to 340B hospitals were unlawful.
 

Related News Articles

Headline
Senate Health, Education, Labor, and Pensions Committee Chairman Bill Cassidy, M.D., R-La., today released a report detailing findings from an investigation鈥
Headline
The AHA April 18 filed friend-of-the-court briefs in three cases in support of Louisiana's 340B contract pharmacy law that prohibits drug companies from鈥
Headline
A Minnesota state court April 15 dismissed a lawsuit filed by PhRMA challenging the state鈥檚 law protecting 340B pricing for contract pharmacy arrangements. The鈥
Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription鈥
Headline
Achieving operational and survey readiness on day one is an issue that many health care facilities professionals continue to grapple with, according to鈥
Headline
The Department of Health and Human Services said its decision to prevent drug companies from implementing a 340B rebate model 鈥渨as within its statutory鈥